These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 22519445)

  • 1. The role of matrix metalloproteinases in essential hypertension.
    Androulakis E; Tousoulis D; Papageorgiou N; Latsios G; Siasos G; Stefanadis C
    Curr Top Med Chem; 2012; 12(10):1149-58. PubMed ID: 22519445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extracellular matrix biology: a new frontier in linking the pathology and therapy of hypertension?
    Tayebjee MH; MacFadyen RJ; Lip GY
    J Hypertens; 2003 Dec; 21(12):2211-8. PubMed ID: 14654734
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imbalance between matrix metalloproteinases and tissue inhibitor of metalloproteinases in hypertensive vascular remodeling.
    Castro MM; Rizzi E; Prado CM; Rossi MA; Tanus-Santos JE; Gerlach RF
    Matrix Biol; 2010 Apr; 29(3):194-201. PubMed ID: 19969080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Matrix turnover.
    Kerrigan JJ; Mansell JP; Sandy JR
    J Orthod; 2000 Sep; 27(3):227-33. PubMed ID: 11099555
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients.
    Ergul A; Portik-Dobos V; Hutchinson J; Franco J; Anstadt MP
    Am J Hypertens; 2004 Sep; 17(9):775-82. PubMed ID: 15363819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of tissue inhibitors of metalloproteinases may reverse severe pulmonary arterial hypertension.
    Tang WL; Guo H; Yang J; Chen B; Wang X
    Cytotherapy; 2011 Apr; 13(4):499-502. PubMed ID: 21105842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extracellular matrix remodeling and matrix metalloproteinases in the vascular wall during aging and in pathological conditions.
    Jacob MP
    Biomed Pharmacother; 2003; 57(5-6):195-202. PubMed ID: 12888254
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of matrix metalloproteinases and tissue inhibitors of metalloproteinases in hypertension. Pathogenesis of hypertension and obesity].
    Trojanek JB
    Postepy Biochem; 2015; 61(4):356-63. PubMed ID: 27048090
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extracellular matrix alterations in hypertensive vascular remodeling.
    Lemarié CA; Tharaux PL; Lehoux S
    J Mol Cell Cardiol; 2010 Mar; 48(3):433-9. PubMed ID: 19837080
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel therapeutic approaches targeting matrix metalloproteinases in cardiovascular disease.
    Briasoulis A; Tousoulis D; Papageorgiou N; Kampoli AM; Androulakis E; Antoniades C; Tsiamis E; Latsios G; Stefanadis C
    Curr Top Med Chem; 2012; 12(10):1214-21. PubMed ID: 22519451
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TIMP3 is the primary TIMP to regulate agonist-induced vascular remodelling and hypertension.
    Basu R; Lee J; Morton JS; Takawale A; Fan D; Kandalam V; Wang X; Davidge ST; Kassiri Z
    Cardiovasc Res; 2013 Jun; 98(3):360-71. PubMed ID: 23524300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mechanisms of extracellular matrix remodeling in dilated cardiomyopathy].
    Pauschinger M; Chandrasekharan K; Li J; Schwimmbeck PL; Noutsias M; Schultheiss HP
    Herz; 2002 Nov; 27(7):677-82. PubMed ID: 12439639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Matrix Metalloproteases in Arterial Hypertension and their Trend after Antihypertensive Treatment.
    Hopps E; Lo Presti R; Caimi G
    Kidney Blood Press Res; 2017; 42(2):347-357. PubMed ID: 28618427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Collagen and elastin degradation by matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase in aortic dissection.
    Ishii T; Asuwa N
    Hum Pathol; 2000 Jun; 31(6):640-6. PubMed ID: 10872655
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: a temporal and spatial window.
    Vanhoutte D; Schellings M; Pinto Y; Heymans S
    Cardiovasc Res; 2006 Feb; 69(3):604-13. PubMed ID: 16360129
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What has been learned about the cardiovascular effects of matrix metalloproteinases from mouse models?
    Janssens S; Lijnen HR
    Cardiovasc Res; 2006 Feb; 69(3):585-94. PubMed ID: 16426591
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cellular turnover and extracellular matrix remodeling in female reproductive tissues: functions of metalloproteinases and their inhibitors.
    Fata JE; Ho AT; Leco KJ; Moorehead RA; Khokha R
    Cell Mol Life Sci; 2000 Jan; 57(1):77-95. PubMed ID: 10949582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of matrix metalloproteinases in melanoma cell invasion.
    Hofmann UB; Houben R; Bröcker EB; Becker JC
    Biochimie; 2005; 87(3-4):307-14. PubMed ID: 15781317
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac mast cell regulation of matrix metalloproteinase-related ventricular remodeling in chronic pressure or volume overload.
    Janicki JS; Brower GL; Gardner JD; Forman MF; Stewart JA; Murray DB; Chancey AL
    Cardiovasc Res; 2006 Feb; 69(3):657-65. PubMed ID: 16376324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Matrix reloaded: the matrix metalloproteinase paradox.
    Panek AN; Bader M
    Hypertension; 2006 Apr; 47(4):640-1. PubMed ID: 16505199
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.